| 前收盘价格 | 3.61 |
| 收盘价格 | 3.63 |
| 成交量 | 2,130,568 |
| 平均成交量 (3个月) | 1,521,353 |
| 市值 | 546,630,848 |
| 市盈率 (P/E TTM) | 18.35 |
| 预期市盈率 (P/E Forward) | 19.53 |
| 价格/销量 (P/S) | 1.39 |
| 股市价格/股市净资产 (P/B) | 2.22 |
| 52周波幅 | |
| 利润日期 | 29 Jul 2026 |
| 营业毛利率 | 11.40% |
| 营业利益率 (TTM) | 9.35% |
| 稀释每股收益 (EPS TTM) | 0.270 |
| 季度收入增长率 (YOY) | 4.10% |
| 季度盈利增长率 (YOY) | -24.20% |
| 总债务/股东权益 (D/E MRQ) | 9.20% |
| 流动比率 (MRQ) | 4.70 |
| 营业现金流 (OCF TTM) | 65.52 M |
| 杠杆自由现金流 (LFCF TTM) | 53.10 M |
| 资产报酬率 (ROA TTM) | 13.80% |
| 股东权益报酬率 (ROE TTM) | 22.29% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | MiMedx Group, Inc | 混合的 | 看跌 |
AIStockmoo 评分
1.4
| 分析师共识 | 2.0 |
| 内部交易活动 | 1.5 |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.5 |
| 平均 | 1.40 |
|
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.71% |
| 机构持股比例 | 70.12% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Essex Woodlands Management, Inc. | 31 Mar 2026 | 28,195,249 |
| Trigran Investments, Inc. | 31 Mar 2026 | 7,175,109 |
| Paradigm Capital Management Inc/Ny | 31 Mar 2026 | 3,410,300 |
| Nantahala Capital Management, Llc | 31 Mar 2026 | 3,397,299 |
| First Light Asset Management, Llc | 31 Mar 2026 | 2,842,892 |
| Punch & Associates Investment Management, Inc. | 31 Mar 2026 | 2,019,718 |
| Marshall Wace, Llp | 31 Mar 2026 | 1,861,146 |
| Qube Research & Technologies Ltd | 31 Mar 2026 | 1,651,519 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BIERMAN JAMES L | 3.64 | - | 50,913 | 185,323 |
| HAWKINS WILLIAM A | 3.64 | - | 50,913 | 185,323 |
| NEWTON TODD | 3.64 | - | 50,913 | 185,323 |
| OLSON TIFFANY | 3.64 | - | 50,913 | 185,323 |
| PUHY DOROTHY E | 3.64 | - | 50,913 | 185,323 |
| 累积净数量 | 254,565 | |||
| 累积净值 ($) | 926,617 | |||
| 累积平均购买 ($) | 3.64 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| OLSON TIFFANY | 董事 | 10 Jun 2026 | 获得 (+) | 50,913 | 3.64 | 185,323 |
| HAWKINS WILLIAM A | 董事 | 10 Jun 2026 | 获得 (+) | 50,913 | 3.64 | 185,323 |
| NEWTON TODD | 董事 | 10 Jun 2026 | 获得 (+) | 50,913 | 3.64 | 185,323 |
| PUHY DOROTHY E | 董事 | 10 Jun 2026 | 获得 (+) | 50,913 | 3.64 | 185,323 |
| BIERMAN JAMES L | 董事 | 10 Jun 2026 | 获得 (+) | 50,913 | 3.64 | 185,323 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合